Trial Profile
A phase II study of ILX651 [tasidotin] administered intravenously daily for five consecutive days every 21 days in patients with hormone-refractory prostate cancer previously treated with docetaxel
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tasidotin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Genzyme Corporation
- 01 Oct 2005 New trial record.